AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18836986 — intervention group
Group type: COMPARATOR
Intervention: Abdominal aortic calcium (AAC)
Number of subjects: 504
Study 17292362 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blastocyst transfer (SBT) on day 5
Number of subjects: 0
Study 17292362 — intervention group
Group type: COMPARATOR
Intervention: Single embryo transfer (SET) on day 3
Number of subjects: 0
Study 17292362 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blastocyst transfer (SBT) after excellent-quality embryos became available
Number of subjects: 0
Study 17292362 — intervention group
Group type: COMPARATOR
Intervention: Single embryo transfer (SET) after excellent-quality embryos became available
Number of subjects: 0
Study 15565613 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units subcutaneously weekly)
Number of subjects: 185
Study 15565613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 15565613 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 185
Study 12171679 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) applied 30 minutes before UVA irradiation.
Number of subjects: 30
Study 12171679 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) with additional pretreatment using AGR-containing vehicle (Eucerin Gel Cream Phase 1) twice daily for 3 and 7 days.
Number of subjects: 30
Study 12171679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sun preparation applied twice daily for 1 week before vacation and SPF 15 sunscreen used 30 minutes before sun exposure.
Number of subjects: 30
Study 12171679 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for acne aestivalis patients.
Number of subjects: 30
Study 12171679 — intervention group
Group type: COMPARATOR
Intervention: Untreated control area during UVA irradiation.
Number of subjects: 30
Study 9762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic COPD patients
Number of subjects: 53
Study 9762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic COPD patients
Number of subjects: 53
Study 9762797 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 53
Study 9762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic vs Hypercapnic COPD
Number of subjects: 53
Study 9762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 53
Study 7848005 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 10 days)
Number of subjects: 100
Study 7848005 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg every two days)
Number of subjects: 100
Study 7848005 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (30 g)
Number of subjects: 100
Study 7848005 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (300,000 U every 3 hours for 16‐28 days)
Number of subjects: 100
Study 3288075 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated intranasal temperature (inhalation of saturated hot air at 42-44 degrees C)
Number of subjects: 78
Study 3288075 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study 30426269 — intervention group
Group type: EXPERIMENTAL
Intervention: Collarless straight tapered stem (Corail®)
Number of subjects: 40
Study 30426269 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact points of the implant with femoral cortical bone
Number of subjects: 40
Study 27545871 — intervention group
Group type: COMPARATOR
Intervention: 25% SLS formulation
Number of subjects: 49
Study 27545871 — intervention group
Group type: COMPARATOR
Intervention: 12.5% SLS formulation
Number of subjects: 49
Study 27545871 — intervention group
Group type: COMPARATOR
Intervention: 3% SLS formulation
Number of subjects: 49
Study 27545871 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference 50% SLS formulation
Number of subjects: 49
Study 27545871 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (600 mg)
Number of subjects: 49
Study 24382130 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) online training
Number of subjects: 540
Study 24283276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber formula (FF)
Number of subjects: 8
Study 24283276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid formula (MF)
Number of subjects: 8
Study 24283276 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 8
Study 20836913 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual medication assessment as part of a Comprehensive Geriatric Assessment (CGA) by physicians (n = 361)
Number of subjects: 1000
Study 20836913 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 339)
Number of subjects: 1000
Study 18323492 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy
Number of subjects: 36
Study 18323492 — intervention group
Group type: COMPARATOR
Intervention: Comparison therapy
Number of subjects: 36
Study 17009827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gibson-Piggott procedure
Number of subjects: 37
Study 14619087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory subhepatic drainage (324 patients)
Number of subjects: 689
Study 14619087 — intervention group
Group type: COMPARATOR
Intervention: Indicated subhepatic drainage (365 patients)
Number of subjects: 689
Study 10973767 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 microg/kg bolus followed by continuous infusion of 0.75 microg/kg/min for 72 hours)
Number of subjects: 181
Study 10973767 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (combined groups)
Number of subjects: 181
Study 10973767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 10973767 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 181
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of history for apnea or respiratory failure
Number of subjects: 137
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of reason for hospitalization
Number of subjects: 137
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cyanosis
Number of subjects: 137
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of respiratory rate
Number of subjects: 137
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of retractions
Number of subjects: 137
Study 8856800 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of oxygen saturation measures
Number of subjects: 137
Study 1501118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (100, 200 and 400 mg)
Number of subjects: 14
Study 1501118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 and 4 mg)
Number of subjects: 14
Study 1501118 — intervention group
Group type: EXPERIMENTAL
Intervention: Methocarbamol (2.25 and 9 g)
Number of subjects: 14
Study 1501118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6440982 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 0
Study 6440982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30850411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (intravenously administered every 8 hours for a total of 600,000 U/day for five consecutive days)
Number of subjects: 880
Study 30850411 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 880
Study 29174695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated oral cholera vaccine (OCV)
Number of subjects: 59635
Study 29174695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59635
Study 26968693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track program (FT)
Number of subjects: 258
Study 26968693 — intervention group
Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 258
Study 25076161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 days before PET/CT scan
Number of subjects: 30
Study 25076161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 30
Study 22851598 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 310
Study 22851598 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH)
Number of subjects: 310
Study 20049753 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg daily
Number of subjects: 146
Study 16773037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release fampridine 25 mg b.i.d. (Group I)
Number of subjects: 91
Study 16773037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release fampridine 40 mg b.i.d. (Group II)
Number of subjects: 91
Study 16773037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 91
Study 15788340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered electrical stimulation
Number of subjects: 22
Study 15788340 — intervention group
Group type: COMPARATOR
Intervention: Non-triggered electrical stimulation
Number of subjects: 22
Study 12236050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal capsule containing 200 mg progesterone
Number of subjects: 24
Study 12236050 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gel containing 90 mg progesterone
Number of subjects: 24
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate NaCl diet (120 mmol/d)
Number of subjects: 39
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (220 mmol/d)
Number of subjects: 39
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl diet (20 mmol/d)
Number of subjects: 39
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 39
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load during intermediate NaCl diet
Number of subjects: 39
Study 9822445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load after each diet
Number of subjects: 39
Study 8126986 — intervention group
Group type: EXPERIMENTAL
Intervention: PZA (2S (E) HRZ/EHR)
Number of subjects: 0
Study 8126986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2912427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy with lovastatin and colestipol
Number of subjects: 10
Study 1098542 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical cholera vaccine with yellow fever vaccine
Number of subjects: 0
Study 1098542 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified fraction vaccine with yellow fever vaccine
Number of subjects: 0
Study 1098542 — intervention group
Group type: COMPARATOR
Intervention: Classical cholera vaccine
Number of subjects: 0
Study 1098542 — intervention group
Group type: COMPARATOR
Intervention: Purified fraction vaccine
Number of subjects: 0
Study 7031741 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 0
Study 7031741 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study 31332988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 28
Study 31332988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training
Number of subjects: 28
Study 28327122 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (20 mg) three times a day
Number of subjects: 120
Study 28327122 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 120
Study 27885221 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Gel B
Number of subjects: 0
Study 24733645 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% portion size
Number of subjects: 50
Study 24733645 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% portion size
Number of subjects: 50
Study 24733645 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% portion size
Number of subjects: 50
Study 24733645 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight status (normal-weight vs obese)
Number of subjects: 50
Study 24733645 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion size condition
Number of subjects: 50
Study 24733645 — intervention group
Group type: COMPARATOR
Intervention: RRVF status
Number of subjects: 50
Study 22995879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy with contemporary antithrombin regimens (bivalirudin or heparin plus glycoprotein IIb/IIIa inhibitor)
Number of subjects: 2475
Study 22995879 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 2475
Study 19090505 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) and Kava
Number of subjects: 28
Study 19090505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18093307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya and related practices (SK&P) - practiced daily for six weeks
Number of subjects: 103
Study 18093307 — intervention group
Group type: COMPARATOR
Intervention: Relaxation in an armchair (control group)
Number of subjects: 103
Study 15102872 — intervention group
Group type: EXPERIMENTAL
Intervention: LE 0.1% (400 microg/day)
Number of subjects: 32
Study 15102872 — intervention group
Group type: EXPERIMENTAL
Intervention: LE 0.2% (800 microg/day)
Number of subjects: 32
Study 15102872 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 0.05% (200 microg/day)
Number of subjects: 32
Study 15102872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11704889 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 presence in patients with multiple sclerosis
Number of subjects: 113
Study 11704889 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 viremia in patients with multiple sclerosis
Number of subjects: 113
Study 11704889 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐7 reactivation in patients with demyelinating diseases of the peripheral nervous system
Number of subjects: 113
Study 11990191 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone
Number of subjects: 20
Study 11990191 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7982184 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release metoclopramide (CRM) 40 mg every 12 hours for 3 days
Number of subjects: 34
Study 7982184 — intervention group
Group type: COMPARATOR
Intervention: Immediate release metoclopramide (IRM) 20 mg every 6 hours for 3 days
Number of subjects: 34
Study 7982184 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release metoclopramide (CRM)
Number of subjects: 34
Study 7982184 — intervention group
Group type: COMPARATOR
Intervention: Immediate release metoclopramide (IRM)
Number of subjects: 34
Study 2661843 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% hypertonic saline (HS)
Number of subjects: 20
Study 2661843 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 20
Study 1064215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine presoaked lens
Number of subjects: 0
Study 1064215 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% pilocarpine presoaked lens
Number of subjects: 0
Study 1064215 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% pilocarpine presoaked lens
Number of subjects: 0
Study 1064215 — intervention group
Group type: COMPARATOR
Intervention: 4% pilocarpine intensive drops
Number of subjects: 0
Study 31104034 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based visual feedback trunk control training
Number of subjects: 24
Study 31104034 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 24
Study 30372781 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (Group 2)
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with spinal narcotic (Group 1)
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with spinal without narcotic (Group 3)
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Nausea or vomiting incidence in Group 1
Number of subjects: 195
Study 30372781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea or vomiting incidence in Group 2
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Nausea or vomiting incidence in Group 3
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Pruritus incidence in Group 1
Number of subjects: 195
Study 30372781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruritus incidence in Group 2
Number of subjects: 195
Study 30372781 — intervention group
Group type: COMPARATOR
Intervention: Pruritus incidence in Group 3
Number of subjects: 195
Study 27834574 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in SALSA (8-week randomized, crossover pilot study)
Number of subjects: 50
Study 27834574 — intervention group
Group type: EXPERIMENTAL
Intervention: Latin dance
Number of subjects: 50
Study 27834574 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in psychosocial factors
Number of subjects: 50
Study 25545629 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 1150
Study 25545629 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 2 mg/day
Number of subjects: 1150
Study 25545629 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1150
Study 23642947 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of Lf/IgF daily for 90 days
Number of subjects: 126
Study 23642947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 20605427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudding with 10 g oat bran DF
Number of subjects: 20
Study 20605427 — intervention group
Group type: COMPARATOR
Intervention: Pudding with no added fibre
Number of subjects: 20
Study 20605427 — intervention group
Group type: COMPARATOR
Intervention: Pudding with 10 g wheat bran DF
Number of subjects: 20
Study 20605427 — intervention group
Group type: COMPARATOR
Intervention: Pudding with 5 g wheat bran DF + 5 g oat bran DF
Number of subjects: 20
Study 19424052 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens with CNS penetration effectiveness (CPE) rank of at least 2
Number of subjects: 101
Study 19424052 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral regimens with CPE rank less than 2
Number of subjects: 101
Study 19424052 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens with CPE rank of at least 2 or more antiretrovirals
Number of subjects: 101
Study 19424052 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral regimens with poorer CNS penetration
Number of subjects: 101
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: MCQ test
Number of subjects: 33
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: CASTest
Number of subjects: 33
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ALS score (one MCQ and one CASTest)
Number of subjects: 33
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement
Number of subjects: 33
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pass/fail decisions
Number of subjects: 33
Study 17467869 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalizability theory
Number of subjects: 33
Study 14572824 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Victim Impact Panel (VIP)
Number of subjects: 0
Study 14572824 — intervention group
Group type: COMPARATOR
Intervention: No Victim Impact Panel (VIP)
Number of subjects: 0
Study 11265104 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone communication
Number of subjects: 0
Study 11265104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fax communication
Number of subjects: 0
Study 11265104 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail communication
Number of subjects: 0
Study 11265104 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing communication
Number of subjects: 0
Study 11265104 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face meetings
Number of subjects: 0
Study 8835070 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month replacement schedule
Number of subjects: 119
Study 8835070 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month replacement schedule
Number of subjects: 119
Study 8835070 — intervention group
Group type: COMPARATOR
Intervention: Non-replacement (control) group
Number of subjects: 119
Study 1572248 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2.5 or 5.0 mg slow intravenous bolus followed by continuous infusion of 1.5‐2.0 mg/h for 48 hours)
Number of subjects: 46
Study 1572248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same mode of administration as captopril)
Number of subjects: 46
Study 1572248 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 46
Study 1572248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3894127 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0
Study 3894127 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 0
Study 30484733 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 48
Study 30484733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High SUV1 (≥6) in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SUV1 (<6) in EWS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: High SUV1 (≥6) in OS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SUV1 (<6) in OS patients
Number of subjects: 77
Study 27645694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ALP level
Number of subjects: 77